Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment
Authors
Keywords
DPP-4 inhibitor, Linagliptin, Efficacy, Safety, Renal impairment, Type 2 diabetes
Journal
Diabetology & Metabolic Syndrome
Volume 5, Issue 1, Pages 25
Publisher
Springer Nature
Online
2013-05-22
DOI
10.1186/1758-5996-5-25
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
- (2012) Odd Johansen et al. Cardiovascular Diabetology
- Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition
- (2012) Swenja Kröller-Schön et al. CARDIOVASCULAR RESEARCH
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETES CARE
- Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study
- (2012) T. Haak et al. DIABETES OBESITY & METABOLISM
- Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus
- (2012) G. Schernthaner et al. DIABETES OBESITY & METABOLISM
- Linagliptin
- (2012) Emma D. Deeks DRUGS
- Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension
- (2012) R. Gomis et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
- (2012) Baptist Gallwitz et al. LANCET
- Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy
- (2011) Anthony H. Barnett ADVANCES IN THERAPY
- The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses
- (2011) Arne Ring et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin*
- (2011) U. Graefe-Mody et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study
- (2011) R. Gomis et al. DIABETES OBESITY & METABOLISM
- Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study
- (2011) R. Kawamori et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study1
- (2011) D. R. Owens et al. DIABETIC MEDICINE
- Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation)
- (2011) André J Scheen Expert Opinion on Drug Metabolism & Toxicology
- Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes
- (2011) Thomas Forst et al. EXPERT OPINION ON PHARMACOTHERAPY
- Glycemic Control and Complications in Type 2 Diabetes Mellitus
- (2010) Mark Stolar AMERICAN JOURNAL OF MEDICINE
- Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
- (2010) M.-R. Taskinen et al. DIABETES OBESITY & METABOLISM
- Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial
- (2010) S. Del Prato et al. DIABETES OBESITY & METABOLISM
- Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes
- (2010) T. Forst et al. DIABETIC MEDICINE
- The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans
- (2010) S. Blech et al. DRUG METABOLISM AND DISPOSITION
- Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects
- (2009) E. U. Graefe-Mody et al. CURRENT MEDICAL RESEARCH AND OPINION
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
- (2009) R. A. DeFronzo DIABETES
- Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes
- (2009) Carolyn F Deacon et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors
- (2009) Manfredi Rizzo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers
- (2008) S. Hüttner et al. JOURNAL OF CLINICAL PHARMACOLOGY
- 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
- (2008) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search